Mosunetuzumab, sold under the brand name Lunsumio, is a monoclonal antibody used for the treatment of follicular lymphoma. It bispecifically binds CD20 and CD3 to engage T-cells. It was developed by Genentech. From Wikipedia
The next step is a European Commission decision, supported by trial results showing PK non-inferiority with high responses under a tolerable safety profile.
